Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854620 · ClinicalTrials.gov registry record · Phase 2
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00854620: Completed Phase 2 study, sponsored by Stanford University.
NCT00854620 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00854620, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Determine time-to-progression (TTP) for an escalating dose schedule for subjects with progressive metastatic renal cell carcinoma treated with sorafenib
Interventions
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00854620
The ClinicalTrials.gov registry entry for NCT00854620 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib is the first listed.
NCT00854620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00854620 about?
NCT00854620 is a clinical study titled "Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer". Determine time-to-progression (TTP) for an escalating dose schedule for subjects with progressive metastatic renal cell carcinoma treated with sorafenib
What is the current status of trial NCT00854620?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2007-12. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00854620?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00854620?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.